Patients with Unresectable Stage III Non-Small Cell Lung Cancer Eligible to Receive Durvalumab in Clinical Practice

被引：0
|
作者：
Furuhashi, K. [1 ]
Hataji, O. [1 ]
Nakamura, Y. [1 ]
Suzuki, Y. [1 ]
Sakaguchi, T. [1 ]
Ito, K. [1 ]
Fujiwara, K. [1 ]
Nishii, Y. [1 ]
Taguchi, O. [1 ]
机构：
[1] Matsusaka Municipal Hosp, Resp Ctr, Matsusaka City, Mie, Japan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
chemoradiotherapy; durvalumab; Non-Small Cell Lung Cancer;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP1.18-19
引用
收藏
页码：S1104 / S1104
页数：1
相关论文
共 50 条
  • [21] A Glimpse Into the Future for Unresectable Stage III Non-Small Cell Lung Cancer
    Bartolomeo, Valentina
    Cortiula, Francesco
    Hendriks, Lizza E. L.
    De Ruysscher, Dirk
    Filippi, Andrea R.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 118 (05): : 1455 - 1460
  • [22] Concurrent chemoradiotherapy for unresectable stage III non-small cell lung cancer
    Vokes, EE
    Crawford, J
    Bogart, J
    Socinski, MA
    Clamon, G
    Green, MR
    CLINICAL CANCER RESEARCH, 2005, 11 (13) : 5045S - 5050S
  • [23] Ineligibility for the PACIFIC trial in unresectable stage III non-small cell lung cancer patients
    Kazutaka Hosoya
    Daichi Fujimoto
    Hayato Kawachi
    Yuki Sato
    Mariko Kogo
    Kazuma Nagata
    Atsushi Nakagawa
    Ryo Tachikawa
    Shinya Hiraoka
    Masaki Kokubo
    Keisuke Tomii
    Cancer Chemotherapy and Pharmacology, 2019, 84 : 275 - 280
  • [24] PACIFIC: An Ocean of Hope in Patients With Stage III Unresectable Non-Small Cell Lung Cancer
    Uprety, Dipesh
    Marinier, David E.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2018, 16 (05): : 458 - 460
  • [25] Ineligibility for the PACIFIC trial in unresectable stage III non-small cell lung cancer patients
    Hosoya, Kazutaka
    Fujimoto, Daichi
    Kawachi, Hayato
    Sato, Yuki
    Kogo, Mariko
    Nagata, Kazuma
    Nakagawa, Atsushi
    Tachikawa, Ryo
    Hiraoka, Shinya
    Kokubo, Masaki
    Tomii, Keisuke
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 84 (02) : 275 - 280
  • [26] Racial disparities in the clinical use of durvalumab for patients with stage III unresectable non-small cell lung cancer treated at Veterans Health Administration facilities.
    Moore, Amanda
    Nooruddin, Zohra
    Reveles, Kelly R.
    Datta, Paromita
    Brannman, Lance
    Cotarla, Ion
    Frankart, Andrew
    Mulrooney, Tiernan
    Jones, Xavier
    Frei, Christopher R.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [27] Real world experience of survival outcomes in consolidative durvalumab in unresectable stage III non-small cell lung cancer (NSCLC)
    Pringle, Nicole
    Fletcher, James
    Arneil, Melissa
    Xu, Wen
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 : 47 - 48
  • [28] Real World Experience of Survival Outcomes in Consolidative Durvalumab in Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)
    Pringle, N.
    Fletcher, J. A.
    Morton, C.
    Mullally, W. J.
    Arneil, M.
    O'Byrne, K.
    Xu, W.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S569 - S569
  • [29] Blood-Based Biomarker Analysis for Predicting Efficacy of Chemoradiotherapy and Durvalumab in Patients with Unresectable Stage III Non-Small Cell Lung Cancer
    Park, Cheol-Kyu
    Lee, Sung-Woo
    Cho, Hyun-Ju
    Oh, Hyung-Joo
    Kim, Young-Chul
    Kim, Yong-Hyub
    Ahn, Sung-Ja
    Cho, Jae-Ho
    Oh, In-Jae
    CANCERS, 2023, 15 (04)
  • [30] Outcomes of patients with unresectable stage III non-small cell lung cancer treated with durvalumab and subsequent therapies after disease progression.
    Dickson, Franco Adjei-Baffour
    Raez, Luis E.
    Dumais, Katerine
    Powery, Herman W.
    Walker, Damaal
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345